---
title: "The Molecular Taxonomy of Primary Prostate Cancer"
image: taxonomy-prostate.png

members:
  - nils-gehlenborg
type: article
year: 2015
publisher: "https://linkinghub.elsevier.com/retrieve/pii/S0092867415013392"
doi: "10.1016/j.cell.2015.10.025"
zotero-key: "Z7MWREK8"
cite:
  authors: "A Abeshouse, J Ahn, R Akbani, A Ally, S Amin, CD Andry, M Annala, A Aprikian, J Armenia, A Arora, JT Auman, M Balasundaram, S Balu, CE Barbieri, T Bauer, CC Benz, A Bergeron, R Beroukhim, M Berrios, A Bivol, T Bodenheimer, L Boice, MS Bootwalla, R Borges dos Reis, PC Boutros, J Bowen, R Bowlby, J Boyd, RK Bradley, A Breggia, F Brimo, CA Bristow, D Brooks, BM Broom, AH Bryce, G Bubley, E Burks, YSN Butterfield, M Button, D Canes, CG Carlotti, R Carlsen, M Carmel, PR Carroll, SL Carter, R Cartun, BS Carver, JM Chan, MT Chang, Y Chen, AD Cherniack, S Chevalier, L Chin, J Cho, A Chu, E Chuah, S Chudamani, K Cibulskis, G Ciriello, A Clarke, MR Cooperberg, NM Corcoran, AJ Costello, J Cowan, D Crain, E Curley, K David, JA Demchok, F Demichelis, N Dhalla, R Dhir, A Doueik, B Drake, H Dvinge, N Dyakova, I Felau, ML Ferguson, S Frazer, S Freedland, Y Fu, SB Gabriel, J Gao, J Gardner, JM Gastier-Foster, N Gehlenborg, M Gerken, MB Gerstein, G Getz, AK Godwin, A Gopalan, M Graefen, K Graim, T Gribbin, R Guin, M Gupta, A Hadjipanayis, S Haider, L Hamel, DN Hayes, DI Heiman, J Hess, KA Hoadley, AH Holbrook, RA Holt, A Holway, CM Hovens, AP Hoyle, M Huang, CM Hutter, M Ittmann, L Iype, SR Jefferys, CD Jones, SJM Jones, H Juhl, A Kahles, CJ Kane, K Kasaian, M Kerger, E Khurana, J Kim, RJ Klein, R Kucherlapati, L Lacombe, M Ladanyi, PH Lai, PW Laird, ES Lander, M Latour, MS Lawrence, K Lau, T LeBien, D Lee, S Lee, KV Lehmann, KM Leraas, I Leshchiner, R Leung, JA Libertino, TM Lichtenberg, P Lin, WM Linehan, S Ling, SM Lippman, J Liu, W Liu, L Lochovsky, M Loda, C Logothetis, L Lolla, T Longacre, Y Lu, J Luo, Y Ma, HS Mahadeshwar, D Mallery, A Mariamidze, MA Marra, M Mayo, S McCall, G McKercher, S Meng, AM Mes-Masson, MJ Merino, M Meyerson, PA Mieczkowski, GB Mills, KRM Shaw, S Minner, A Moinzadeh, RA Moore, S Morris, C Morrison, LE Mose, AJ Mungall, BA Murray, JB Myers, R Naresh, J Nelson, MA Nelson, PS Nelson, Y Newton, MS Noble, H Noushmehr, M Nykter, A Pantazi, M Parfenov, PJ Park, JS Parker, J Paulauskis, R Penny, CM Perou, A Piché, T Pihl, PA Pinto, D Prandi, A Protopopov, NC Ramirez, A Rao, WK Rathmell, G Rätsch, X Ren, VE Reuter, SM Reynolds, SK Rhie, K Rieger-Christ, J Roach, AG Robertson, B Robinson, MA Rubin, F Saad, S Sadeghi, G Saksena, C Saller, A Salner, F Sanchez-Vega, C Sander, G Sandusky, G Sauter, A Sboner, PT Scardino, E Scarlata, JE Schein, T Schlomm, LS Schmidt, N Schultz, SE Schumacher, J Seidman, L Neder, S Seth, A Sharp, C Shelton, T Shelton, H Shen, R Shen, M Sherman, M Sheth, Y Shi, J Shih, I Shmulevich, J Simko, R Simon, JV Simons, P Sipahimalani, T Skelly, HJ Sofia, MG Soloway, X Song, A Sorcini, C Sougnez, S Stepa, C Stewart, J Stewart, JM Stuart, TB Sullivan, C Sun, H Sun, A Tam, D Tan, J Tang, R Tarnuzzer, K Tarvin, BS Taylor, P Teebagy, I Tenggara, B Têtu, A Tewari, N Thiessen, T Thompson, LB Thorne, DP Tirapelli, SA Tomlins, FA Trevisan, P Troncoso, LD True, MC Tsourlakis, S Tyekucheva, E Van Allen, DJ Van Den Berg, U Veluvolu, R Verhaak, CD Vocke, D Voet, Y Wan, Q Wang, W Wang, Z Wang, N Weinhold, JN Weinstein, DJ Weisenberger, MD Wilkerson, L Wise, J Witte, CC Wu, J Wu, Y Wu, AW Xu, SS Yadav, L Yang, L Yang, C Yau, H Ye, P Yena, T Zeng, JC Zenklusen, H Zhang, J Zhang, J Zhang, W Zhang, Y Zhong, K Zhu, E Zmuda"
  published: "*Cell* **163**(4):1011-1025"
---
There is substantial heterogeneity among primary prostate cancers, evident in the spectrum of molecular abnormalities and its variable clinical course. As part of The Cancer Genome Atlas (TCGA), we present a comprehensive molecular analysis of 333 primary prostate carcinomas. Our results revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1). Epigenetic profiles showed substantial heterogeneity, including an IDH1 mutant subset with a methylator phenotype. Androgen receptor (AR) activity varied widely and in a subtype-specific manner, with SPOP and FOXA1 mutant tumors having the highest levels of AR-induced transcripts. 25% of the prostate cancers had a presumed actionable lesion in the PI3K or MAPK signaling pathways, and DNA repair genes were inactivated in 19%. Our analysis reveals molecular heterogeneity among primary prostate cancers, as well as potentially actionable molecular defects.